2 Biotech Stocks to Buy Hand Over Fist in February
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not they moved in tandem with the market in January. One month of strong (or poor) returns means little in the grand scheme of things.To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these two companies could both produce outsized returns to patient investors.Continue reading
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not they moved in tandem with the market in January. One month of strong (or poor) returns means little in the grand scheme of things.
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these two companies could both produce outsized returns to patient investors.
